Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

George Francis Murphy, M.D.

Title
Institution
Department
Address
Phone
Fax
Profile Picture

Biography
1976
Induction
1976
Sheard-Sanford Award (Honorable Men.)
1976
Woodbury Alumni Award, Medicine
1982
Election
1984
Benjamin Castleman Award
1987
John Morgan Society
1987
Long Course Director, Service Award
1988
Arthur K. Doolittle Award
1988 - 1989
Diagnostic Pathology Faculty
1988
Election
1988
Leaders' Society
1991
Election to Organization
1991
Herman Beerman Endowed Chair
1992
Teaching Award, Class of 1995
1992
Whitaker Health Sciences Foundation Award
1993
Attending Teaching Award, Dermatology
1993
Merlin Trumbull Lectureship
1994
Keynote Address
1994 - 1998
Short Course Faculty
1995
Faculty Teaching Award, Class of 1995
1997
Chair, Board of Directors
1997
Institutional Representative
1997
U.S. Delegate
1998
Schleifstein Lectureship
1999
Keynote Address
1999
Quest Visiting Professorship in Pathology
2000
Proctor&Gamble Lectureship
2001
Expert Advisory Panel on Skin Tumors
2005
Honorary Master of Arts Degree
2006
Distinguished Academic Achievement Award
2007
Walter Putchar Annual Lectureship

Overview
Dr. Murphy’s program in funded basic investigation has been ongoing continuously since 1984 in the form of R01 grants and via participation in Program Project initiatives. The current focus of Dr. Murphy's research is elucidation of the cellular and molecular mechanisms responsible for cutaneous cytotoxic reactions, including graft-versus-host disease subsequent to allogeneic stem cell transplantation for childhood and adult leukemia/lymphoma. In addition, a major collaboration involving Brigham Plastic and Reconstructive Surgery and the MIT Biomaterials Department focuses on tissue stem cell biology and cutaneous regenerative medicine. One goal of this work is to define pathways responsible for scarless regeneration that typifies fetal, but not post-natal, human skin. Dr. Murphy also serves as the Director of the Tissue and Cell Analysis Core for the Harvard Skin Disease Research Center (SDRC) as well as for the Biospecimen Access and Analysis Core for the Harvard Specialized Program for Research Excellence (SPORE) in skin cancer. For research contributions concerning Langerhans cell histiocytosis, he received the Benjamin Castleman Award of the International Academy of Pathology. In 1991, he was elected into the American Society for Clinical Investigation for which he also served as an Institutional Representative. His work in the area of neuropeptide regulation of Langerhans cell function was recognized as one of the 50 most significant scientific breakthroughs worldwide for the year 1993 by the magazine, Discover. His most recent collaborative interaction with the laboratory of Dr. Markus Frank of Boston’s Children’s Hospital has recently fostered the first biomarker identification and therapeutically relevant targeting of melanoma stem cells (January 2008 cover article, Nature). He has served as a regular term member of the General Medicine A Study Section for the NIH.

Research
The research activities and funding listed below are automatically derived from NIH ExPORTER and other sources, which might result in incorrect or missing items. Faculty can login to make corrections and additions.
  1. P01AI106684 (RAY, ANURADHA) May 15, 2015 - May 31, 2020
    NIH/NIAID
    Immune Airway-Epithelial Interactions in Steroid-Refractory Severe Asthma
    Role: Co-Principal Investigator
  2. P01AI108545 (VIGNALI, DARIO AA) May 15, 2015 - Apr 30, 2020
    NIH/NIAID
    Synergies among inhibitory receptors in tolerance, cancer and antiviral immunity
    Role: Co-Principal Investigator
  3. R01CA158467 (FRANK, MARKUS H.) Sep 1, 2012 - Jun 30, 2017
    NIH/NCI
    Immunology of human malignant melanoma initiating cells
    Role: Co-Principal Investigator
  4. P50CA093683 (KUPPER, THOMAS S.) Sep 30, 2001 - Jan 31, 2014
    NIH/NCI
    SPORE in Skin Cancer
    Role: Co-Principal Investigator
  5. P01CA077401 (FLOMENBERG, NEAL) Apr 1, 1999 - Mar 31, 2004
    NIH/NCI
    BIOLOGIC &CLINICAL PROPERTIES OF CD4 STRUCTURAL ANALOGS
    Role: Co-Principal Investigator

Bibliographic
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Zhong CS, Russell-Goldman E, Murphy GF, Nambudiri VE. Paraneoplastic Hypomyopathic Dermatomyositis Associated With EGFR Exon-20 Insertion NSCLC. J Thorac Oncol. 2019 Jun; 14(6):e128-e130. PMID: 31122566.
    Citations:    
  2. Leavitt D, Wells M, Abarzua P, Murphy GF, Lian CG. Differential distribution of the epigenetic marker 5-hydroxymethylcytosine occurs in hair follicle stem cells during bulge activation. J Cutan Pathol. 2019 May; 46(5):327-334. PMID: 30719726.
    Citations:    
  3. Tappenbeck N, Schröder HM, Niebergall-Roth E, Hassinger F, Dehio U, Dieter K, Kraft K, Kerstan A, Esterlechner J, Frank NY, Scharffetter-Kochanek K, Murphy GF, Orgill DP, Beck J, Frank MH, Ganss C, Kluth MA. In vivo safety profile and biodistribution of GMP-manufactured human skin-derived ABCB5-positive mesenchymal stromal cells for use in clinical trials. Cytotherapy. 2019 May; 21(5):546-560. PMID: 30878384.
    Citations:    
  4. Liu Y, Xu S, Zu T, Li F, Sang S, Liu C, An Y, Mi B, Orgill DP, Murphy GF, Lian CG. Reversal of TET-mediated 5-hmC loss in hypoxic fibroblasts by ascorbic acid. Lab Invest. 2019 Mar 05. PMID: 30837678.
    Citations:    
  5. Krezdorn N, Lian CG, Wells M, Wo L, Tasigiorgos S, Xu S, Borges TJ, Frierson RM, Stanek E, Riella LV, Pomahac B, Murphy GF. Chronic rejection of human face allografts. Am J Transplant. 2019 Apr; 19(4):1168-1177. PMID: 30312535.
    Citations:    Fields:    
  6. Tsai JJ, Velardi E, Shono Y, Argyropoulos KV, Holland AM, Smith OM, Yim NL, Rao UK, Kreines FM, Lieberman SR, Young LF, Lazrak A, Youssef S, Fu YY, Liu C, Lezcano C, Murphy GF, Na IK, Jenq RR, Hanash AM, Dudakov JA, van den Brink MRM. Nrf2 regulates CD4+ T cell-induced acute graft-versus-host disease in mice. Blood. 2018 Dec 27; 132(26):2763-2774. PMID: 30381375.
    Citations:    Fields:    
  7. Aires DJ, Yoshida M, Richardson SK, Bai M, Liu L, Moreno R, Lazar AJF, Wick JA, Rich BE, Murphy G, Blumberg RS, Fuhlbrigge RC, Kupper TS. T-cell trafficking plays an essential role in tumor immunity. Lab Invest. 2019 01; 99(1):85-92. PMID: 30353131.
    Citations:    Fields:    
  8. Ordikhani F, Uehara M, Kasinath V, Dai L, Eskandari SK, Bahmani B, Yonar M, Azzi JR, Haik Y, Sage PT, Murphy GF, Annabi N, Schatton T, Guleria I, Abdi R. Targeting antigen-presenting cells by anti-PD-1 nanoparticles augments antitumor immunity. JCI Insight. 2018 10 18; 3(20). PMID: 30333312.
    Citations:    Fields:    
  9. Kollar B, Shubin A, Borges TJ, Tasigiorgos S, Win TS, Lian CG, Dillon ST, Gu X, Wyrobnik I, Murphy GF, Pomahac B, Libermann TA, Riella LV. Increased levels of circulating MMP3 correlate with severe rejection in face transplantation. Sci Rep. 2018 Oct 08; 8(1):14915. PMID: 30297859.
    Citations:    Fields:    
  10. Sweeney JG, Liang J, Antonopoulos A, Giovannone N, Kang S, Mondala TS, Head SR, King SL, Tani Y, Brackett D, Dell A, Murphy GF, Haslam SM, Widlund HR, Dimitroff CJ. Loss of GCNT2/I-branched glycans enhances melanoma growth and survival. Nat Commun. 2018 08 22; 9(1):3368. PMID: 30135430.
    Citations:    Fields:    Translation:HumansAnimalsCells
  11. Ward C, Volpe G, Cauchy P, Ptasinska A, Almaghrabi R, Blakemore D, Nafria M, Kestner D, Frampton J, Murphy G, Buganim Y, Kaji K, García P. Fine-Tuning Mybl2 Is Required for Proper Mesenchymal-to-Epithelial Transition during Somatic Reprogramming. Cell Rep. 2018 Aug 07; 24(6):1496-1511.e8. PMID: 30089261.
    Citations:    Fields:    
  12. Wu D, Hu D, Chen H, Shi G, Fetahu IS, Wu F, Rabidou K, Fang R, Tan L, Xu S, Liu H, Argueta C, Zhang L, Mao F, Yan G, Chen J, Dong Z, Lv R, Xu Y, Wang M, Ye Y, Zhang S, Duquette D, Geng S, Yin C, Lian CG, Murphy GF, Adler GK, Garg R, Lynch L, Yang P, Li Y, Lan F, Fan J, Shi Y, Shi YG. Glucose-regulated phosphorylation of TET2 by AMPK reveals a pathway linking diabetes to cancer. Nature. 2018 07; 559(7715):637-641. PMID: 30022161.
    Citations: 4     Fields:    
  13. Wang DM, Kraft S, Rohani P, Murphy GF, Besaw RJ, Karia PS, Morgan FC, Schmults CD. Association of Nodal Metastasis and Mortality With Vermilion vs Cutaneous Lip Location in Cutaneous Squamous Cell Carcinoma of the Lip. JAMA Dermatol. 2018 Jun 01; 154(6):701-707. PMID: